ERBB2 and breast cancer: Importantly, the proportion of patients achieving pCR after neoadjuvant chemotherapy differs between molecular subtypes, with the lowest pCR rates (2%–11%) reported in hormone receptor‐positive (HRpos), HER2‐negative (HER2neg) BC.6